Q3 2023 Earnings Presentation
Q3 2023 Vision Care
Double-digit Vision Care growth reflects strength in
contact lenses and eye drops, including acquired
products, and pricing
+
+
Alcon
●
●
●
●
Product innovation, including toric modalities of Precision 1, Total30 and
Dailies Total1
Price increases across contact lens portfolio
Strong demand for portfolio of eye drops, including Rocklatan and
Rhopressa; 11 percentage points of growth contribution to Ocular Health
from products acquired in 2022
Price increases across ocular health portfolio
Declines in legacy lenses
1. Constant currency growth is a non-IFRS measure. An explanation of non-IFRS measures can be found in the Appendix.
$908
$558
Net Sales
(USD $M)
$350
3Q22
$1,027
$612
$415
3Q23
Contact lenses
Ocular health
(USD) (CC)¹
13% 13%
10% 9%
19% 20%
10View entire presentation